Market Newsdesk

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

SAN DIEGO–(BUSINESS WIRE)–Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “REVB.” The CUSIP number for the common stock following the reverse stock split will be 76135L705.

The reverse stock split is intended to increase the market price per share of the Company’s common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. Proportionate adjustments will be made to the conversion and exercise prices of the company’s warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company’s equity incentive plans.

Separately, the Company also announced that it’s ongoing PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete enrollment this month and topline data expected shortly after. For more information on Revelation, please visit www.RevBiosciences.com.

Information for Stockholders

Upon the effectiveness of the reverse stock split, each sixteen shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s relative interest in the Company’s equity, except to the extent that the reverse stock split would have resulted in a stockholder owning a fractional share. Holders of common stock otherwise entitled to a fractional share as a result of the Reverse Stock Split because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will be rounded down to the nearest whole share. The reverse stock split will not change the par value of the common stock or modify the rights or preferences of the common stock. The Company’s transfer agent, Continental Stock Transfer & Trust Co., will maintain the book-entry records for the Company’s common stock. Registered stockholders holding pre-split shares of the Company’s common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker’s particular processes, and will not be required to take any action in connect with the reverse stock split. Continental Stock Transfer & Trust Co. can be reached at (212) 509-4000 or (800)-509-5586.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.

For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250702832451/en/

Company Contacts

Mike Porter

Investor Relations

Porter LeVay & Rose Inc.

Email: [email protected]

Chester Zygmont, III

Chief Financial Officer

Revelation Biosciences Inc.

Email: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials

MEDIA:

Logo

Union Pacific Celebrates its 163^rd Birthday with New Commemorative No. 1616 Lincoln Locomotive in President Lincoln’s Hometown

Springfield Honored with Train Town USA Designation as part of the Festivities

SPRINGFIELD, Ill.–(BUSINESS WIRE)–
Union Pacific Railroad celebrated its 163^rd birthday today in the hometown of its famed founder – President Abraham Lincoln – with the help of numerous dignitaries and its newest commemorative locomotive that honors Lincoln’s role in laying the foundation for America’s best-in-the-world freight rail system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627695928/en/

The event was sponsored by Union Pacific, the Lincoln Presidential Foundation, Looking for Lincoln and Hanson Professional Services. Special guests at the event included Springfield Mayor Misty Buscher, Illinois Railroad Association President Tim Butler, Lincoln Presidential Foundation President and CEO Erin Mast, National Park Service Superintendent Chris Collins, State Sen. Doris Turner, State Sen. Mike Coffey, Union Pacific Vice President – Public Affairs Liisa Stark and Union Pacific Senior Director – Public Affairs in Illinois Tom Evenson.

Lincoln founded Union Pacific with the signing of the historic Pacific Railway Act on July 1, 1862, which authorized construction of the nation’s first transcontinental railroad network.

“Union Pacific is incredibly proud of our heritage, and we are honored to share this special locomotive in the hometown of the man who brought our railroad to life and unleashed economic prosperity,” said Liisa Stark, vice president of Public Affairs for Union Pacific Railroad. “We think Lincoln would have been proud of the vital role railroads serve today in delivering the goods and products essential for everyday life in America.”

The Lincoln Locomotive, which serves as a traveling ambassador for Union Pacific, made its debut on April 30 in North Little Rock, where it was painted by Union Pacific employees. It is painted in a color scheme unique to Lincoln’s era and serves as a nod to another famed locomotive – No. 119 – which was one of two locomotives present at the Golden Spike Ceremony in Promontory Summit, Utah, in 1869, which marked the completion of the nation’s first transcontinental railroad.

Springfield was also designated as an official Train Town USA community. The honor celebrates the towns and communities along Union Pacific’s tracks, many of which exist because of the railroad. Just as they were more than 100 years ago, these communities remain vital to the railroad’s success.

“It is an incredible honor for Springfield to host Union Pacific Railroad on this historic milestone and to welcome the Lincoln Locomotive to the hometown of our 16th president. Abraham Lincoln’s vision helped unite a nation, and that legacy lives on through the railroads that continue to connect communities and drive economic progress. Being named a Train Town USA is a proud recognition of Springfield’s enduring role in our nation’s rail history,” said Springfield Mayor Misty Buscher.

Railroads are at the heart of the U.S. economy and touch nearly every industry including vehicles, chemicals, energy, agriculture, metals, minerals, forest products, consumer goods and more. Union Pacific’s more than 30,000 employees deliver essential items from lumber and drywall to build homes to corn and wheat to make bread and cereal.

ABOUT UNION PACIFIC

Union Pacific (NYSE: UNP) delivers the goods families and businesses use every day with safe, reliable and efficient service. Operating in 23 western states, the company connects its customers and communities to the global economy. Trains are the most environmentally responsible way to move freight, helping Union Pacific protect future generations. More information about Union Pacific is available at www.up.com.

www.up.com

www.facebook.com/unionpacific

www.twitter.com/unionpacific

ABOUT THE LINCOLN PRESIDENTIAL FOUNDATION

Established in 2000, the Lincoln Presidential Foundation is a 501(c)(3) nonprofit public charity headquartered in Illinois. It is the only national foundation focused on increasing access to history, educational programs, exhibits, and sites highlighting the life and legacy of Abraham Lincoln. The Foundation works in cooperation and partnership with others locally, nationally, and globally. Its vision is a world where freedom and democracy flourish, inspired by the life and work of Abraham Lincoln. Learn more at lincolnpresidential.org.

ABOUT LOOKING FOR LINCOLN

The Looking for Lincoln Heritage Coalition is the coordinating entity for the 43-county Abraham Lincoln National Heritage Area. It is a partnership of organizations and individuals dedicated to enhancing the communities and landscapes of central Illinois through recognition and support of their significant natural, cultural, and historical legacies. Few individuals have so profoundly influenced American history as did Abraham Lincoln. Millions around the world are inspired by the story of Lincoln’s rise from humble beginnings to President of the United States, his qualities of integrity and courage and his decisive leadership – traits that carried a fragile nation through one of its most trying periods. For more information about the Looking for Lincoln Heritage Coalition and the Abraham Lincoln National Heritage Area, go to www.lookingforlincoln.org.

ABOUT HANSON PROFESSIONAL SERVICES

Hanson Professional Services Inc. is a national, employee-owned consulting firm with a global reach. Established in 1954, Hanson provides multidiscipline services to clients from six markets: railway, infrastructure, aviation, government, industry and power. For decades, Hanson has appeared as a Top 500 design firm in Engineering News-Record’s listing of premier U.S. design firms and has received numerous workplace and project-related awards. Hanson is proud to provide design engineering, program management and construction observation services for the $570 million Springfield Rail Improvements Project in Springfield, Illinois.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250627695928/en/

Union Pacific Media Contact: Kristen South at 402-544-5034 or [email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Rail Transport Logistics/Supply Chain Management Other Transport

MEDIA:

Photo

Union Pacific’s No. 1616 Lincoln Locomotive, with the Illinois State Capitol in the background.

Photo

Union Pacific celebrated its 163rd birthday Tuesday, July 1, in the hometown of its founder – President Abraham Lincoln.

Logo

Bank of Hawai‘i Announces New Vice Chair and Chief Financial Officer Bradley S. Satenberg

HONOLULU–(BUSINESS WIRE)–Bradley “Brad” S. Satenberg has been promoted to vice chair and chief financial officer at Bank of Hawaiʻi, following the retirement of Chief Financial Officer Dean Shigemura. In his newly expanded role, he will oversee Bank of Hawai‘i’s planning and forecasting, financial accounting and reporting, regulatory financial reporting, corporate taxation, and the overall budget and forecast for the company.

This thoughtful leadership transition has been the focus of long-term and intentional planning. To prepare for his new role and ensure a smooth transition, Satenberg served as senior executive vice president and deputy to Shigemura since he joined the bank in July 2024. Shigemura will remain with the bank as a consultant through June 2026, providing further continuity and strategic financial counsel.

With over 30 years of extensive experience in the financial services industry, Satenberg is a seasoned professional with an exceptional track record. Prior to joining the bank, Satenberg served as senior vice president and chief financial officer of Luther Burbank Savings and director of investor relations for Luther Burbank Corporation in Los Angeles, managing finance and accounting for the publicly held financial institution since 2018. Over the course of his career, he also served as executive vice president and chief financial officer of 1^st Century Bancshares, Inc., and managing director and deputy chief financial officer of Imperial Capital Bancorp, Inc., both in California, as well as several other leadership roles in various organizations. Satenberg earned his Bachelor of Business Administration degree in accounting from the University of Texas at Austin.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250701115212/en/

Media Inquiries

Melissa Torres-Laing

Email: [email protected]

Phone: 808-694-8384

Mobile: 808-859-1703

KEYWORDS: United States North America Hawaii

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–
Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The data provides additional evidence of benefits of ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury. Service related mTBI results in a high incidence of persistent physical and emotional challenges for patients, impacting their quality of life and that of their families. Additionally, a history of mTBI increases the risk of dementia diagnosis later in life.

Data analysis for this study, supported by the US Department of Defense and conducted in collaboration with US Department of Veterans Affairs investigators and the Seattle Institute of Biomedical and Clinical Research, has been concluded, demonstrating that ALPHA-1062 administration following blast induced mTBI, results in a notable reduction in indices of TBI associated neuropathology.

ALPHA-1062 administration reduced the brain levels of three toxic forms of a brain protein Tau. One of these forms (pTau 217) has been suggested to identify TBI patients at greater risk of long-term cognitive decline. It is also one of the earliest emerging biomarkers in Alzheimer’s disease. A second form of toxic Tau (pTau-S202/T205) can be found in very early-stage pathology in the brains of Alzheimer’s patients before the appearance plaques and tangles. The third form (pTau 231) is elevated in early Alzheimer’s disease and TBI. Taken together, reduction of these toxic forms of pTau suggests a potential role for ALPHA-1062 in the treatment of TBI and that this may additionally positively impact the risk of later developing Alzheimer’s disease.

Additional benefits of ALPHA-1062 were observed following blast trauma. High dose ALPHA-1062 reduced the numbers of myeloid cells which play a critical role in neuroinflammation and tissue repair, as well as the number of astrocytes, which regulate neurotransmitters like glutamate and GABA to support neuronal health. These changes are consistent with reduced neuroinflammation following ALPHA-1062 administration. Finally, nerve growth factor receptor expression, which plays an important role in neuronal survival, was increased in an ALPHA-1062 dose-dependent manner. “These outcomes are in agreement with those of an earlier pre-clinical study in a moderate TBI animal model, both studies demonstrated protective effects of ALPHA-1062, providing support for the continued development of ALPHA-1062 for the treatment of traumatic brain injury,” said Denis Kay, ACI’s Chief Scientific Officer.

Alpha Cognition’s next steps in this program will be to complete formulation of ALPHA-1062 for sublingual administration and conduct a bridging pharmacokinetic study vs. ZUNVEYL® (Benzgalantamine) and an existing intranasal formulation of ALPHA-1062.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ALPHA-1062 formulated as a delayed release oral tablet ZUNVEYL (Benzgalantamine) is FDA approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as a sublingual formulation for cognitive Impairment with mTBI.

Forward-looking Statements

This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential benefits of the licensing agreement for the development and commercialization of ZUNVEYL in Asia (excluding Japan), Australia and New Zealand, the Company’s timing and planned activities to launch ZUNVEYL in the U.S. and China, the timing for the Company’s planned corporate update call, the potential timing for the availability of ZUNVEYL in the U.S. and China, the potential future developments of ZUNVEYL in China, the potential market size for ZUNVEYL in China, the Company’s business strategy for the launch of ZUNVEYL in China, the market size and demand for ZUNVEYL in China, the Company’s potential growth opportunities in China, the timing and results of the Company’s milestone payments for China, the Company’s regulatory submissions in China, and the potential regulatory approval and commercialization of the Company’s products in China. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form S-1/A registration statement as filed with the SEC on November 6, 2024 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250701475460/en/

For further information:

Investor Relations

[email protected]

https://www.alphacognition.com/

KEYWORDS: United States North America Canada Texas

INDUSTRY KEYWORDS: Research Pharmaceutical Mental Health White House/Federal Government Defense Clinical Trials Science Biotechnology Neurology Health Military Public Policy/Government

MEDIA:

Logo

American Express Announces 2025 Preliminary Stress Capital Buffer Requirement

NEW YORK–(BUSINESS WIRE)–
American Express Company (NYSE: AXP) today announced that the Federal Reserve set the company’s preliminary Stress Capital Buffer (“SCB”) requirement at 2.5 percent, effective October 1, 2025 through September 30, 2026, based on the results of the 2025 Comprehensive Capital Analysis and Review process. This is the minimum SCB requirement under the applicable regulations and is consistent with American Express’ previously disclosed SCB in effect through September 30, 2025.

“The results of this year’s stress test once again reaffirmed our strong capital position and the earnings power of our resilient business model,” said Christophe Le Caillec, Chief Financial Officer. “We remain focused on executing our disciplined capital allocation strategy, prioritizing investments in our business to drive sustainable long-term growth, while maintaining a strong balance sheet and returning excess capital to our shareholders.”

As previously disclosed, American Express increased its quarterly dividend on common shares by 17 percent to $0.82 per share beginning with the first quarter 2025 dividend declaration, and returned $5.4 billion of capital to shareholders via share repurchases during the 12 months ended March 31, 2025.

The SCB requirement is subject to final confirmation by the Federal Reserve, which is expected by August 31, 2025.

ABOUT AMERICAN EXPRESS

American Express (NYSE: AXP) is a global, premium payments and lifestyle brand powered by technology. Our colleagues around the world back our customers with differentiated products, services and experiences that enrich lives and build business success.

Founded in 1850 and headquartered in New York, American Express’ brand is built on trust, security, and service, and a rich history of delivering innovation and Membership value for our customers. With a hundred million merchant locations on our global network in around 200 countries and territories, we seek to provide the world’s best customer experience every day to a broad range of consumers, small and medium-sized businesses, and large corporations.

For more information about American Express, visit americanexpress.com, americanexpress.com/en-us/newsroom/, and ir.americanexpress.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements, which are subject to risks and uncertainties, contain words such as “expect,” “intend,” “plan,” “aim,” “will,” “may,” “should,” “could,” “would,” “continue” and similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Actual results may differ from those set forth in the forward-looking statements due to a variety of factors, including those described in American Express’ Annual Report on Form 10-K for the year ended December 31, 2024 and its other reports filed with the SEC. The company undertakes no obligation to update or revise any forward-looking statements.

Source: American Express Company

Location: Global

View source version on businesswire.com: https://www.businesswire.com/news/home/20250701344119/en/

Media:

Amanda Miller, [email protected], +1.408.219.0563

Deniz Yigin, [email protected], +1.332.999.0836

Investors/Analysts:

Kartik Ramachandran, [email protected], +1.212.640.5574

Amanda Blumstein, [email protected], +1.212.640.5574

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Other Professional Services Professional Services Finance

MEDIA:

Logo